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Abstract
Introduction: We aimed to investigate whether recognized hormonal predictors of rheumatoid arthritis (RA) also
influence the severity of RA.
Methods: One hundred thirty-four incident RA cases identified by four different local and national registers, who
had participated in a community-based health survey between 1991 and 1996, were included. By a retrospective
structured review of the medical records, information on the use of disease-modifying antirheumatic drugs
(DMARDs), erosions on radiographs, rheumatoid factor (RF) status, and disability measured by using the health
assessment questionnaire (HAQ) were collected. The variables were added to the SPSS TwoStep Cluster Analysis to
reveal natural groupings of RA severity. Known hormonal predictors analyzed were breastfeeding history, history of
oral contraceptive (OC) use, and menopausal age.
Results: The mean age at RA diagnosis was 63.4 years; 72% were RF positive, and 28% had received biological
treatment. Three clusters were identified, one with severe RA, one with mild/moderate RF-positive RA, and one
with mild/moderate RF-negative RA. A significant difference (P = 0.005) was found in the distribution of clusters
between patients with a history of early menopause compared with those with menopause after 45 years, with a
higher proportion with mild/moderate RF-negative RA in the early-menopause subset. No major difference in
severity of the disease was noted depending on OC use or history of breastfeeding.
Conclusions: Early menopause was associated with a milder form of RA. Hormonal changes may influence
pathways that are distinct from those leading to severe, progressive disease.
Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory
disease, with a female predominance [1,2]. Hormonal
factors have been suggested to influence the risk of RA.
A reduced incidence occurs during pregnancy, and also
an increased rate of clinical remission among women
with RA who become pregnant [3]. Low testosterone
levels have been described in both women and men
with RA [4-6], and a high incidence of RA is found dur-
ing the peri- and postmenopausal period in women [7],
suggesting that hormones and hormonal changes may
influence pathogenesis and disease progression. The dis-
ease is heterogeneous and now often is regarded as a
syndrome of several distinct phenotypes instead of being
a single disease [8]. Hormonal factors could have diverse
influences on older onset of RA compared with younger
onset, as well as on seropositive and seronegative
disease.
The effect of oral contraceptives (OCs) on RA has been
the subject of many studies and meta-analyses [9-11],
with diverging results. Variances in methods, doses, and
types of OC, as well as population differences, have been
proposed to explain some of these controversies. It has
been suggested that OCs alter the course of RA, instead
of acting as a predictor, and are associated with a milder
type of disease and less disability [12,13]. In a previous
study, we did not find any impact of a history of OC use
on the risk of RA [2]. We did, however, demonstrate an
association for early menopause (≤ 45 years) with
increased risk of RA, and a protective effect of long-term
breastfeeding [2,14] on postmenopausal onset of RA.
Jorgensen et al. [13] reported that the mean duration of
breastfeeding was longer in women who subsequently
developed a severe RA phenotype. To our knowledge, no
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studies have been conducted on the influence of meno-
pausal age on the long-term outcome of RA.
The aim of this study was to investigate whether hor-
monal factors, such as breastfeeding history, OC use,
and menopausal age, influence the severity of RA.
Materials and methods
Malmö Diet and Cancer Study
The Malmö Diet and Cancer Study (MDCS) is a popula-
tion-based prospective cohort study performed in
Malmö, Sweden, between 1991 and 1996. Baseline
examination included a self-administered questionnaire,
anthropometric measuring, and blood sampling, stored
in a biological bank. All individuals living in Malmö and
aged 44 through 74, on 1 January 1991, were invited. In
total, of 30,477 subjects (18,326 women) were recruited.
Language problems and mental retardation were the
only exclusion criteria [15].
By linking the MDCS to four registers (a community-
based RA-register, the local outpatient clinic administra-
tive register, the National Hospital Discharge Register, and
the National Cause of Death Register), we identified indivi-
duals who had developed RA after their participation in
the MDCS (≥ 1 year before RA diagnosis). Based on a
review of the medical records, patients were classified
according to the 1987 American College of Rheumatology
(ACR) criteria for RA [16]. Female patients who been diag-
nosed before December 31, 2004, and fulfilled the ACR
criteria from 1987, were included in the present study.
Clinical-outcome measures
In a separate, structured review of all medical records, per-
formed by one of the authors (MP), data were collected on
clinical-outcome measures up to the date of the review
(between February and October 2010) or to the last day of
follow-up. Information on treatment with Disease Modify-
ing Anti-Rheumatic Drugs, (DMARDs), including bio-
logics, was collected. Treatment with biologics for RA in
Sweden is to a great extent based on national evidence-
based guidelines. These were first formulated in 2002 and
were updated in 2004 and since 2008 on an annual basis
[17]. Although changes in the guidelines occurred over the
years, biologics are still recommended mainly for patients
with severe RA that is refractory to traditional DMARD
therapy [17]. Based on this, ever use of biologics can be
used as a surrogate marker for severe disease. Data on
exposure to biologics were also derived from linkage to a
regional follow-up system for patients with rheumatologic
diseases receiving such treatment, the South Swedish
Arthritis Treatment Group (SSATG) register [18]. The
SSATG was established in 1999 and includes patients
from a total of 10 rheumatology centers, of which six are
in the Region Skåne area in southern Sweden (~1.3 million
inhabitants). The register has been compared with
pharmaceutical sales data and found to cover more than
90% of anti-TNF-treated patients in the area [18]. Further
clinical information collected from medical records
included data on prednisolone treatment at diagnosis (or
within 1 month before or after the time of diagnosis),
severe extraarticular manifestations (pericarditis, pleuritis,
vasculitis, Felty syndrome, glomerulonephritis, and inter-
stitial lung disease) [19], and disability measured by using
the Health Assessment Questionnaire (HAQ) [20] at diag-
nosis and after 1 year (the closest value within 6 to 18
months was accepted), 5 years (4 to 6 years accepted), and
10 years (8 to 12 years accepted) from diagnosis. The
HAQ is a self-administered questionnaire, consisting of
questions about of 20 activities of daily living in eight cate-
gories. This instrument is useful in monitoring the
patient’s course and response to therapy and in assessing
functional disability. The HAQ form is distributed to all
patients with RA before visiting the outpatient clinic at the
University hospital in Malmö. The scale ranges from 0 to
3, with higher scores indicating greater disability. To be
able to classify HAQ scores in relation to disease duration,
the exact date of diagnosis was set as the day a rheumatol-
ogist gave a definitive (ICD-10) diagnosis of RA, indepen-
dent of the beginning of symptoms. Data on rheumatoid
factor (RF) tests and tests for antibodies to cyclic citrulli-
nated peptides (anti-CCP) were retrieved from the data-
bases of the two clinical immunology laboratories in the
area. Patients with at least one positive test for RF or anti-
CCP were considered positive for this marker.
All available reports on radiographs of hands and feet
were reviewed. Based on the radiology reports, patients
were classified as ever having arthritic erosions, typical
of RA, or not. Data on smoking history, time of cessa-
tion, if applicable, number of children given birth to,
and ever use of hormonal replacement therapy (HRT)
were collected.
Hormonal exposure variables
Data on age at menopause, breastfeeding history, use of
OC, and level of formal education were retrieved from the
self-administered questionnaire used in the MDCS, and
assessed on average 5.5 years before RA diagnosis. All
female individuals in the present sample who answered
the MDCS questionnaire were 45 years of age or older. If
they reported menopause beginning after the age of 45, or
answered that they had not yet reached menopause, they
were classified in the group “normal/late menopause.” If
they had reached menopause before the age of 46, they
were included in the group “early menopause.”
Breastfeeding history was stratified into never having
breastfed, cumulative breastfeeding of 1 to 12 months, or
cumulative breastfeeding of ≥ 13 months, as previously
described [2]. Based on information on the use of OC,
cases were divided into three groups; never-users, 1 to
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5 years of use, and > 5 years of use. Nonresponders were
excluded from the analyses.
Statistics
Clusters of RA severity were identified by using SPSS
TwoStep Clustering algorithm (version 19). This algo-
rithm allows the use of both categoric and continuous
variables in the same model. Selected outcome measures
were based on data availability and clinical plausibility:
biologic treatment, presence of radiographic erosions,
RF status, and disability 5 years after diagnosis, mea-
sured by using the HAQ. The HAQ score at 5 years was
included in the model because data were available in a
greater number of patients at this time point. These out-
come measures were added to the algorithm, and differ-
ent numbers of natural groupings were explored.
The algorithm initially identified six clusters, but these
were considered difficult to interpret from a clinical
standpoint, and the small sample for each cluster was a
concern. In the subsequent analysis, the algorithm was
pre-set to identify three clusters. The model identifying
three clusters was chosen because these clusters were
considered to reflect clinically relevant phenotypes. Only
after this decision had been made was the distribution of
such clusters by baseline hormonal exposures examined
by using the c2 test.
For the individual outcome parameters, only descrip-
tive data without formal statistical comparisons were
presented. Analysis of covariance (ANCOVA) was used
to compare mean HAQ between subsets defined by hor-
monal predictors, adjusted for age.
The regional research ethics committee for southern
Sweden approved the study. All patients gave their
informed consent to be included in the Malmö RA regis-
ters and the MDCS database. No informed consent was
obtained specifically for the present study.
Results
Of the 136 incident female patients previously described
[2], two patients on long-term follow-up were found to
develop a phenotype compatible with erosive osteoarthri-
tis rather than RA, and were therefore excluded from this
study. Median time from inclusion in MDCS to RA diag-
nosis was 5.5 years. The mean age at RA diagnosis was
63.4 years, and the mean disease duration at the last
follow-up was 10.1 years (SD, 3.5). Ninety-four (71.2%)
were RF positive. Twenty-eight percent received biologic
treatment during follow-up, and the median number of
DMARDs used was two. Almost 60% of the patients had
documented radiographic erosions, and 5% had severe
extraarticular manifestations (Table 1). Availability of
data on HAQ was limited and varied for different time
points (Table 1), but no major differences was noted in
the proportions with missing HAQ at different time
points between those with early and normal/late meno-
pause (52% versus 46% at diagnosis, 52% versus 36% at
1 year, 24% versus 33% at 5 years, and 52% versus 52% at
10 years).
All patients with complete data for the relevant out-
come variables (n = 90) were included in the cluster
analysis. Three different clusters of RA severity were
identified, of which cluster I represented a severe RA
phenotype; cluster II, a moderate/mild RF-positive RA
phenotype; and cluster III, a moderate/mild RF-negative
RA phenotype (Table 2).
Because HAQ-score values had a normal distribution
among patients in cluster I, and a skewed distribution in
clusters II and III, means with standard deviations as
well as medians with interquartile ranges are presented
(Table 2). In the group with severe RA, all patients had
been treated with biologics; 89% were RF positive, 85%
had documented erosions, and the mean HAQ score
after 5 years was 1.17. In the mild/moderate RF-positive
and RF-negative clusters, no one had received biologics;
the proportions with documented erosions was lower,
and mean HAQ scores after 5 years were lower than
those in the severe RA cluster (Table 2).
Hormonal factors and disease outcome
The duration of follow-up was similar in patients with a
history of early versus normal/late menopause (Table 3)
Table 1 Patient characteristics
All patients
n = 134
Mean age at diagnosis; years (SD) (range) 63.2 (8.3) (47-80)
Mean follow-up time; years (SD) 10.1 (3.5)
RF positive (%) 94/132 (71.2)
Anti-CCP positive (%) 34/57 (59.6)
Smoking at diagnosis (%) 39/118 (33.1)
Low formal education (< 8 years of school) (%) 66/128 (49.3)
Prednisolone at diagnosis (%) 39/120 (32.5)
Biological treatment ever (%) 37/133 (27.8)
Number of used DMARDS; median (IQR) 2 (1-3)
> 3 DMARDs used (%) 30 (22.4)
DMARDS in combination (%) 54 (40.3)
Documented radiographic erosions (ever) (%) 71/125 (56.8)
Severe extraarticular manifestations (%) 7 (5.2)
Median HAQ at diagnosisa 0.87
Median HAQ 1 year after diagnosisa 0.75
Median HAQ 5 years after diagnosisa 0.75
Median HAQ 10 years after diagnosisa 0.88
CCP, cyclic citrullinated peptide; DMARD, disease-modifying antirheumatic
drug; HAQ, Health Assessment Questionnaire; IQR, interquartile range; RF,
rheumatoid factor; SD, standard deviation. aData available for HAQ at
diagnosis in 70 cases, for HAQ at 1 year in 82 cases, for HAQ at 5 years in 92
cases, and for HAQ at 10 years in 63 cases.
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and also similar across strata of length of breastfeeding
(Table 4) and use of OC (Table 5). No major difference
was found in the mean age at diagnosis between patients
with early menopause (65.2 years) and normal/late meno-
pause (62.8 years). A significant difference appeared in the
distribution of patients between the clusters, depending on
menopausal age (P = 0.005), with more women with early
menopause developing RF-negative mild/moderate RA
(Figure 1). The age-adjusted mean HAQ scores were
lower among women with early menopause at all time
points (Table 3). No significant interaction occurred
between age at RA diagnosis and early versus normal/late
menopause status in analyses of their impact on HAQ
(data not shown). In analyses adjusted for age, a borderline
association was found between early menopause and lower
HAQ at diagnosis (b = -0.38; 95% CI, -0. 78 to 0.01), with
a similar tendency at other time points (data not shown).
No significant differences in the distribution of clus-
ters of clinical-outcome measures were seen in analysis
by breastfeeding history (P = 0.88) or previous use of
OC (P = 0.56) (Tables 4 and 5). Women who had used
OC > 5 years tended to be in the cluster of severe RA,
and the mean age at RA diagnosis was lower in this sub-
set (Table 5). Overall, individuals who were younger at
diagnosis were more likely to be treated with biologics
(data not shown). No major differences were noted in
age at diagnosis, depending on breastfeeding history
(Table 4).
Women who hade normal/late menopause were more
likely to receive treatment with biologics and DMARDS
in combination, but no major differences appeared in the
number of different DMARDS used during the follow-up
(Table 3).
Discussion
We previously showed that hormonal factors such as
early menopause and breastfeeding history influence the
risk of RA [2,14]. In particular, early menopause was a
Table 2 Distribution of clusters of clinical outcomes
Cluster I: Severe RA (n
= 26)
Cluster II: Mild/moderate seropositive
RA (n = 25)
Cluster 3: Mild/moderate seronegative
RA (n = 39)
Treated with biologics (ever) 100% 0 0




HAQ after 5 years
Mean (SD) 1.17 (0.61) 0.74 (0.61) 0.88 (0.66)
Median (IQR) 1.00 (0.72-1.66) 0.63 (0.38-0.88) 0.88 (0.25-1.25)
HAQ, Health Assessment Questionnaire; IQR, interquartile range; RF, rheumatoid factor; SD, standard deviation.
Table 3 Clinical outcomes by age at menopause
Early menopause
(< 46 years) (n = 25)a
Normal/late menopause
(≥ 46 years) (n = 102)a
Mean age at diagnosis; years (SD) 65.2 (6.94) 62.8 (8.48)
Mean follow-up time; years (SD) 10.5 (3.0) 10.1 (3.6)
> 3 DMARDs used (%) 5/25 (20.0) 23/101 (22.8)
DMARDs in combination (%) 8/25 (32.0) 45/101 (44.6)
Biological treatment ever (%) 3/25 (12.0) 33/101 (32.7)
Documented radiographic erosions (ever) (%) 14/23 (60.9) 52/96 (54.2)
RF positive (%) 11/25 (44.0) 78/100 (78.0)
Mean HAQ at diagnosis (CI)b 0.58 (0.22-0.93) (n = 12) 0.96 (0.79-1.12) (n = 55)
Mean HAQ 1 year after diagnosis (CI)b 0.45 (0.08-0.83) (n = 12) 0.86 (0.70-1.02) (n = 65)
Mean HAQ 5 years after diagnosis (CI)b 0.88 (0.60-1.15) (n = 19) 0.90 (0.76-1.05) (n = 68)
Mean HAQ 10 years after diagnosis (CI)b 0.67 (0.34-1.00) (n = 12) 0.98 (0.82-1.14) (n = 49)
Cluster distribution (P = 0.005)
Severe RA (%) 3 (15.8%) 23 (34.8%)
Mild/moderate seropos RA (%) 5 (26.3%) 30 (45.5%)
Mild/moderate seroneg RA (%) 11 (57.9%) 13 (19.7%)
CI, confidence Interval; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SD, standard deviation. aIn case of missing data, numbers (n) indicated for
each variable. bAdjusted for age at diagnosis.
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robust risk factor for RA [14]. In this study, we demon-
strated that early menopause predicts a milder type of
RA.
Estrogen is suggested to suppress cellular immunity
directly but to stimulate the humoral immune system
[21]. A decrease in estrogen levels may thus contribute
to a T-cell differentiation skewed toward the T-helper 1
(Th1) subset. This has previously been implicated as an
important part of the pathogenesis of RA [22,23].
Further studies should examine the impact of the timing
of menopause on immunologic and inflammatory path-
ways leading to RA.
Dysfunctions of the hypothalamic-pituitary-adrenocor-
tical axis (HPA axis), the hypothalamic-pituitary-gonadal
(HPG axis), and the autonomic nervous system have all
been suggested to be a part of the complex pathogenesis
of RA [24,25]. Similar observations have been made in
primary Sjögren syndrome [26]. A gradual decline in the
function of the HPG axis is considered a key element in
the development of menopause [27,28]. We propose that





Breastfeeding > 12 months
(n = 19)a
Mean age at diagnosis; years (SD) 63.6 (8.37) 62.8 (8.30) 64.2 (8.27)
Mean follow-up time; years (SD) 9.6 (3.4) 10.3 (3.7) 10.5 (2.8)
> 3 DMARDs used (%) 8/43(18.6) 17/71 (23.9) 5/19 (26.3)
DMARDs in combination (%) 14/43 (32.6) 32/71 (45.1) 8/19 (42.1)
Biological treatment ever (%) 10/43(23.3) 21/71 (29.6) 6/19 (31.6)
Documented radiographic erosions (ever) (%) 25/39 (64.1) 36/70 (51.4) 10/16 (62.5)
RF positive (%) 28/43 (65.1) 53/71 (74.6) 13/18 (72.2)
Mean HAQ at diagnosis (CI)b 0.91 (0.64-1.18) (n = 21) 0.89 (0.69-1.09) (n = 39) 0.86 (0.47-1.25) (n = 10)
Mean HAQ 1 year after diagnosis (CI)b 0.76 (0.49-1.03) (n = 24) 0.86 (0.66-1.06) (n = 44) 0.68 (0.32-1.03) (n = 14)
Mean HAQ 5 years after diagnosis (CI)b 0.91 (0.68-1.14) (n = 31) 0.90 (0.72-1.09) (n = 49) 0.85 (0.48-1.22) (n = 12)
Mean HAQ 10 years after diagnosis (CI)b 0.78 (0.50-1.06) (n = 16) 0.94 (0.76-1.13) (n = 38) 1.08 (0.70-1.45) (n = 9)
Cluster distribution (P = 0.88)
Severe RA (%) 8/31 (25.8) 15/48 (31.2) 3/11 (27.3)
Mild/moderate seropos RA (%) 13/31 (41.9) 20/48 (41.7) 6/11 (54.5)
Mild/moderate seroneg RA (%) 10/31 (32.3) 13/48 (27.1) 2/11 (18.2)
CI, confidence interval; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SD, standard deviation. aIn case of missing data, numbers (n) indicated for
each variable. bAdjusted for age at diagnosis.
Table 5 Clinical outcomes by history of use of oral contraceptives
Never used (n = 67)a 1-5 years of use (n = 17)a > 5 years of use (n = 43)a
Mean age at diagnosis; years (SD) 66.2 (7.82) 58.8 (8.19) 60.1 (7.17)
Mean follow-up time; years (SD) 10.4 (3.3) 9.9 (3.1) 10.0 (3.8)
> 3 DMARDs used (%) 11/67 (16.4) 4/17 (23.5) 14/42 (33.3)
DMARDs in combination (%) 26/67 (38.8) 8/17 (47.1) 20/42 (47.6)
Biological treatment ever (%) 14/67 (20.9) 4/17 (23.5) 19/42 (45.2)
Documented radiographic erosions (ever) (%) 37/62 (59.7) 10/17 (58.8) 20/40 (50.0)
RF positive (%) 46/66 (69.7) 10/16 (62.5) 34/43 (79.1)
Mean HAQ at diagnosis (CI)b 0.75 (0.53-0.97) (n = 34) 0.93 (0.42-1.43) (n = 6) 1.06 (0.81-1.30) (n = 27)
Mean HAQ 1 year after diagnosis (CI)b 0.83 (0.61-1.05) (n = 39) 0.64 (0.20-1.09) (n = 9) 0.81 (0.56-1.06) (n = 29)
Mean HAQ 5 years after diagnosis (CI)b 0.93 (0.75-1.11) (n = 47) 0.80 (0.46-1.15) (n = 13) 0.86 (0.62-1.10) (n = 26)
Mean HAQ 10 years after diagnosis (CI)b 0.79 (0.59-1.00) (n = 33) 1.20 (0.77-1.63) (n = 7) 1.00 (0.75-1.26) (n = 21)
Cluster distribution (P = 0.56)
Severe RA (%) 12/47 (25.5) 3/12 (25.0) 11/25 (44.0)
Mild/moderate seropos RA (%) 21/47 (44.7) 5/12 (41.7) 9/25 (36.0)
Mild/moderate seroneg RA (%) 14/47 (29.8) 4/12 (33.3) 5/25 (20.0)
CI, confidence interval; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SD, standard deviation. aIn case of missing data, numbers (n) indicated for
each variable. bAdjusted for age at diagnosis.
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women with a less-responsive HPG axis, leading to an
increased risk of early menopause, may also have a pri-
marily malfunctioning or “sluggish” HPA axis. A reduced
response of the HPA axis to inflammation would make
them more susceptible to develop a chronic inflamma-
tory disease. In support of this, it has been found that
women who develop RA later in life have higher birth
weight than do normal controls [29,30], and some data
link high birth weight with a less-responsive HPA func-
tion later in life [31]. This may reflect an impact of HPA
function on chronic inflammation in general, rather than
on the specific pathogenesis of erosive arthritis.
In this study, women with a history of early menopause
in whom RA developed were more likely to have a mild
disease course, and less likely to progress to severe RA.
This suggests that different predictors may be associated
with distinct clinical outcomes. For example, other
known risk factors for RA, such as the shared epitope of
HLA-DRB1, and smoking, may, in comparison with early
menopause, be more specifically associated with a severe
phenotype of RA [32,33].
A recent study [12] suggested that OC use is associated
with mild RA and demonstrated a reduction of disability,
measured by HAQ over time, in former OC users, com-
pared with nonusers. Furthermore, current OC users had
lower HAQ scores at baseline and over time than did pre-
vious users. Jorgensen et al. [13] found that OC is both
protective for RA and associated with a mild phenotype in
individuals who develop RA. Yet another study did not
find a protective effect of current use of OC for RA [34].
Because our patients were older, with a mean age at diag-
nosis of 63 years (range, 47 to 80 years), only one patient
reported current use of OC at diagnosis, and we could
therefore not address the effect of current use of OC. The
mean time between OC use and RA diagnosis was 20
years, which may explain the limited impact of former OC
use on the severity of RA. In our sample, the former users
rather tended to develop a more-severe RA, at least by
some outcome measures. This could be biased by their
younger age at diagnosis. In particular, the difference in
the proportion treated with biologics may be due to more
extensive prescription of such drugs for younger indivi-
duals with RA, as was the case in the present study and
also reported in a recent national survey [35].
Barrett et al. [36] suggested that breastfeeding is a risk
factor for a more-severe inflammatory polyarthritis in a
small group of genetically susceptible women, based on
the linkage between HLA-DRB1 alleles and the prolactin
gene on chromosome 6 [37]. In a prospective short-term
study of pregnant women with inflammatory polyarthri-
tis, they found that women who breastfed after a first
pregnancy had a more-severe disease 6 months postpar-
tum compared with non-breastfeeders and previous
breastfeeders [36]. However, in the present study, we
could not demonstrate any significant long-term effect
of breastfeeding on the severity of RA. Our study design
excludes the smaller group of women who develop RA
during their younger years, which could affect our
results. The immune-stimulating effect of prolactin
could also be short term, and breastfeeding could have a
different long-term immune-modulating effect, sug-
gested by the results from the Nurses Health Study [38]
and our previous results [2].
Limitations of this study include the retrospective data
collection, because information in medical records is
sometimes incomplete and not always coherent, due to
diverse assessments by different physicians. Because risk-
factor information and clinical records are two comple-
tely unrelated sources of information, it is unlikely that
such incompleteness is differential between risk factor-
exposure categories. Nevertheless, the relatively large
proportion of missing data of HAQ at specific time
points is a limitation. Because some physicians may be
less prone to collect HAQ routinely, and this may also
change over time, we cannot exclude a systematic bias
based on this. However, no major differences were found
in the proportions with missing HAQ between those
with early and normal/late menopause.
Because of differences in management practice, the
methods used to define clusters of disease severity may
not be valid in other populations. Another limitation is
the relatively small sample size, which affects analyses of
subsets with different risk-factor profiles.
Strengths include the prospective assessment of hor-
mone-related factors before disease onset, which limits
the risk of recall bias, and the population-based
approach, which reduces the risk of selection bias.
Conclusions
We report that early menopause is associated with a
mild type of RA among women with disease onset after
Figure 1 Distribution of clusters of clinical outcomes defining
disease severity by age at menopause. P = 0.005.
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45 years of age. Hormonal changes may influence path-
ways that are distinct from those leading to severe, pro-
gressive disease. To our knowledge, this is the first
study on the impact of menopausal age on the severity
of RA, and our findings must be confirmed in other stu-
dies of larger samples. Such studies require that data on
the exposure (that is, age at menopause) have been col-
lected in a consistent and valid manner. If our results
are confirmed, it may in the future be relevant to check
for early menopause in women with RA.
Key messages
• Early menopause is associated with a mild serone-
gative RA phenotype.
• Breastfeeding history and former use of oral con-
traceptives did not influence the severity of RA.
• Hormonal changes may influence pathways leading
to a mild type of rheumatoid arthritis.
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